BMJ新闻:WHO宣布几内亚已终止埃博拉病毒的传播

2016-01-02 MedSci MedSci原创

最后一名埃博拉病毒感染者二次检测时为阴性后,42天后即2015年12月29日WHO宣布终结埃博拉病毒在几内亚的传播。

最后一名埃博拉病毒感染者二次检测时为阴性后42天后即2015年12月29日WHO宣布终结埃博拉病毒在几内亚的传播。

三个受埃博拉病毒影响最严重的国家中,几内亚是最后一个宣布终止此疾病传播的国家。2015年11月7日,塞拉利昂宣布已阻断埃博拉病毒的传播途径,而利比里亚早在2015年9月3日就已宣布阻断了埃博拉病毒的传播。

对于此宣告,WHO非洲地区负责人Matshidiso Moeti说道,“这是第一次,这三个国家(几内亚、利比里亚和塞拉利昂)都中断了埃博拉病毒的传播途径。对于各国政府、团体以及合作伙伴的应对这一流行病的决心,我表示赞扬。在我们努力建立有弹性的医疗保健系统时,我们需要时刻保持警惕,以确保我们可迅速停止任何可能在2016年出现的新的突发事件。”

几内亚现在进入了为期90天的强化监督阶段,以确保任何埃博拉病毒感染患者在传播病毒给其他人之前便能被迅速识别。

埃博拉病毒最新爆发的一次始于2013年12月下旬,原始爆发地为盖凯杜、几内亚,并蔓延到邻国利比里亚和塞拉利昂,最终,通过地面传播和空中旅行传播到其他七个国家。

2015年3月至9月之间,埃博拉病毒出现了10次新的小爆发或疾病活动。这或是幸存者人群体内持续存在的病毒重新出现所导致。

埃博拉病毒感染的幸存者在初次感染前很久便已存在宿主病毒,而且很多人存在病毒感染的使人衰弱的并发症,如关节疼痛和精神健康问题。

十月份,英国的一名护士Pauline Cafferkey塞拉利昂工作感染埃博拉病毒,随后在英国的一家医院接受治疗并于2015年1月出院。但是10月,她又因脑膜炎,埃博拉病毒感染所致,而再次住院接受治疗。11月份, 经过治疗Cafferkey体内清除了病毒,不再接受隔离治疗。

原始出处:

Zosia Kmietowicz. Ebola transmission ends in Guinea. BMJ 2015; 351 doi: http://dx.doi.org/10.1136/bmj.h7014.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1650344, encodeId=8d1e16503445f, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Wed Jul 20 02:35:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847832, encodeId=da2b184e832db, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat Nov 19 22:35:00 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54664, encodeId=b33e5466440, content=好东西,值得分享,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:35:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51732, encodeId=20cc51e3241, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Mon Jan 04 15:53:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296450, encodeId=907c129645045, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Mon Jan 04 09:35:00 CST 2016, time=2016-01-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1650344, encodeId=8d1e16503445f, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Wed Jul 20 02:35:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847832, encodeId=da2b184e832db, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat Nov 19 22:35:00 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54664, encodeId=b33e5466440, content=好东西,值得分享,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:35:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51732, encodeId=20cc51e3241, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Mon Jan 04 15:53:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296450, encodeId=907c129645045, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Mon Jan 04 09:35:00 CST 2016, time=2016-01-04, status=1, ipAttribution=)]
    2016-11-19 gaoxiaoe
  3. [GetPortalCommentsPageByObjectIdResponse(id=1650344, encodeId=8d1e16503445f, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Wed Jul 20 02:35:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847832, encodeId=da2b184e832db, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat Nov 19 22:35:00 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54664, encodeId=b33e5466440, content=好东西,值得分享,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:35:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51732, encodeId=20cc51e3241, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Mon Jan 04 15:53:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296450, encodeId=907c129645045, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Mon Jan 04 09:35:00 CST 2016, time=2016-01-04, status=1, ipAttribution=)]
    2016-01-08 andruhn

    好东西,值得分享,学习了!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1650344, encodeId=8d1e16503445f, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Wed Jul 20 02:35:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847832, encodeId=da2b184e832db, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat Nov 19 22:35:00 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54664, encodeId=b33e5466440, content=好东西,值得分享,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:35:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51732, encodeId=20cc51e3241, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Mon Jan 04 15:53:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296450, encodeId=907c129645045, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Mon Jan 04 09:35:00 CST 2016, time=2016-01-04, status=1, ipAttribution=)]
    2016-01-04 xiaotaiyang1

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1650344, encodeId=8d1e16503445f, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Wed Jul 20 02:35:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847832, encodeId=da2b184e832db, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat Nov 19 22:35:00 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54664, encodeId=b33e5466440, content=好东西,值得分享,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:35:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51732, encodeId=20cc51e3241, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Mon Jan 04 15:53:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296450, encodeId=907c129645045, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Mon Jan 04 09:35:00 CST 2016, time=2016-01-04, status=1, ipAttribution=)]

相关资讯

世卫组织:未来20年全球癌症患者或增五成

近日,美国临床肿瘤学会议落幕,而根据世界卫生组织发布的《全球癌症报告2014》,2012年全球癌症患者及死亡病例均有所增加,其中,近一半新增癌症病例出现在亚洲,其中大部分在中国,中国新增癌症病例居第一位。《2012中国肿瘤登记年报》也表明,过去30年间,肺癌死亡率在中国上升了465%,已取代肝癌成为中国首位恶性肿瘤死亡原因。10年后全球癌症患者将近2000万报告描述和分析了全球180多个国家的28

《WHO慢性乙型肝炎预防、关怀和治疗指南》中文版发布

2015年5月15日上午,中文版《WHO慢性乙型肝炎预防、关怀和治疗指南》(以下简称为WHO乙肝指南)正式发布。本指南为首个针对慢性乙肝患者进行预防、关怀和治疗的世卫组织指南。指南概览指南建议是按照慢性乙肝患者连续一体关怀体系的结构编写,从初始对疾病分期和治疗指征的评估,开始一线抗病毒治疗,对疾病进展、药物毒性及肝细胞癌发生的监测,到治疗失败时改用二线药物。建议涵盖各年龄段及各种族成人患者。指

WHO和UNAIDS发布青少年健康保健新标准

由WHO和UNAIDS发布的青少年质量卫生保健服务全球标准,旨在帮助各国改善青少年健康保健的质量。现有的医疗服务往往不能为世界青少年(10-19岁儿童)提供良好的质量。许多遭受精神健康障碍,物质滥用,营养不良,故意伤害,和慢性疾病的青少年没有获得重要的预防和护理服务。同时,这对健康产生终生影响的许多行为开始于青春期。“这些标准提供了简单而强大的步骤,可以使富裕和贫穷的国家都可以立即采取这些步骤来改

WHO:2015年重大卫生问题回顾

回顾2015年,全球取得了多项重大公共卫生成就,但与此同时,也面临着诸多公共卫生的挑战和威胁。2015年,世卫组织针对重大卫生问题发布了一系列报告,并提供新的建议以帮助各国改善人们的健康。 本专辑谨此回顾2015年的主要卫生事件。 1-4月 采取行动避免每年1600万人过早死亡 全球每年有3800万人死于心脏病、肺病、脑卒中、癌症和糖尿病等非传染性疾病,其中有1600万人过早(即7

WHO:世界抗生素耐药性实况报道及战略目标

重要事实 如今,抗生素耐药性是对全球卫生的最大威胁。它会影响每个人,无论其年龄和国籍。 抗生素耐药性是自然发生的,但在人类和动物间误用抗生素会加速发生耐药的过程。 越来越多的感染(比如肺炎、结核和淋病)变得更难治疗,原因在于用于治疗感染的抗生素不如原来有效。 抗生素耐药性会导致更长的住院时间,更高的医疗费用和更多死亡。 概况 抗生素是用于